Quarterly report pursuant to Section 13 or 15(d)

Net Loss per Share

v3.23.1
Net Loss per Share
 3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Net Loss per Share
Note 9: Net Loss per Share
The following table provides the computation of basic and diluted net loss per share:
Three Months Ended March 31,
2023 2022
(in thousands, except per share data)
Net loss attributable to Class A common stockholders–basic and diluted $ (9,199) $ (10,577)
Weighted average Class A common shares outstanding–basic and diluted 41,579  41,579 
Net loss per share attributable to Class A common stockholders–basic and diluted $ (0.22) $ (0.25)
Shares of Class V common stock do not share in the earnings or losses of P3 Health Partners, Inc. and are therefore not participating securities. As such, separate presentation of basic and diluted net income per share for Class V common stock under the two-class method is not required. The following table presents potentially dilutive securities excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive.
Three Months Ended March 31,
2023 2022
(in thousands)
Stock warrants (1)
11,248 10,819
Stock options (1)
5,487 2,134
Shares of Class V common stock (2)
201,972 202,025
Total 218,707 214,978
____________________
(1)    Represents the number of instruments outstanding at the end of the period. Application of the treasury stock method would reduce this amount if they had a dilutive effect and were included in the computation of diluted net loss per share.
(2)    Shares of Class V common stock at the end of the period, including shares tied to unvested Common Units, are considered potentially dilutive shares of Class A common stock under the application of the if-converted method.